Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

Figure 2

Progression-Free Survival related to response. Kaplan-Meier plot illustrating progression-free survival (PFS) in patients with metastasized breast cancer who received liposomal pegylated doxorubicin (PLD) monotherapy. Plotted according to radiographic response after completion of PLD, median PFS was 10.0 months for patients with complete (CR) or partial rememission (PR), 11.9 months with stable disease (SD), 2.8 months with progressive disease (PD), and 2.4 months in which response could not be evaluated (NE), which was significantly different when pooled over strata (P < 0.001). Pairwise comparisons showed no PFS difference between patients with CR/PR and SD.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us